Entos Pharmaceuticals, led by University of Alberta researcher Dr. John Lewis, has selected two promising vaccine prototypes to start testing in people.The Government of Canada has granted Lewis $4.2 million to take the project to the next step, part of the Canadian Institutes of Health Research rapid research funding competition, which awarded $109 million to 139 research teams across the country this month.[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]The Entos vaccine is DNA-based.